Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatitis B (J Lim, Section Editor)

New Advances in Hepatitis B Vaccination for Adults

Authors: Qingyao Daniel Huang, Seng-Gee Lim

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

The mainstay of elimination of hepatitis B virus is through primary prevention by vaccination recommended by the World Health Organization. This review seeks to update readers on the performance of the current second-generation vaccine and the challenges including primary and secondary vaccine failure, as well as compliance and coverage.

Recent Findings

Primary vaccine failure in children may be overcome by HBIG and antiviral therapy in high-risk pregnancies, while in adults, a number of strategies to address this include intradermal delivery, double-dose vaccination, improved adjuvants, and a third-generation vaccine with pre-S1 and pre-S2 proteins. However, there is still no accepted standard therapy for primary vaccine failure. Secondary vaccine failure is less problematic with 3.9% of vaccines developing anti-HBc antibody, but only one reported case of chronicity has developed after vaccination.

Summary

The current second-generation prophylactic hepatitis B vaccines have performed extremely well, but there remain some challenges with regard to vaccine failure. A number of different strategies have been used to overcome this. Overall vaccine failure constitutes a relatively small proportion of vaccinees.
Literature
1.
2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.PubMed
3.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.PubMed
4.
Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158–68.PubMed
5.
Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78(2):169–77.PubMed
6.
Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1(5):377–85.PubMed
7.
Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine. 1988;6(4):299–303.PubMed
8.
Klimek JJ, Brettman L, Neuhaus E, Garibaldi RA. A multi-hospital hepatitis B vaccine program: prevalence of antibody and acceptance of vaccination among high-risk hospital employees. Infect Control. 1985;6(1):32–4.PubMed
9.
Möst J, Larcher C, Vogetseder W, Prodinger WM, Huemer HP, Ebenbichler CF, et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine. 1992;10(11):740–1.PubMed
10.
Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990;8 Suppl:S69–73; discussion S79–80.
11.
• Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):811–32 A systematic review of Engerix B showing seroprotection rates of more than 90% in adults with an acceptable safety profile.
12.
13.
Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board Pediatr Infect Dis J. 1999;18(1):23–4.PubMed
14.
Destefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Pharmacoepidemiol Drug Saf. 2007;16(6):705–7 author reply 707-708.PubMed
15.
16.
17.
• Auta A, Adewuyi EO, Kureh GT, Onoviran N, Adeloye D. Hepatitis B vaccination coverage among health-care workers in Africa: a systematic review and meta-analysis. Vaccine. 2018. Review showing suboptimal hepatitis B vaccine coverage among health care workers in Africa and describes reasons for poor compliance.
18.
Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine. 1990;8(Suppl):S129–33 discussion S134–138.PubMed
19.
Froehlich H, West DJ. Compliance with hepatitis B virus vaccination in a high-risk population. Ethn Dis. 2001;11(3):548–53.PubMed
20.
Panhotra BR, Saxena AK, Al-Hamrani HA, Al-Mulhim A. Compliance to hepatitis B vaccination and subsequent development of seroprotection among health care workers of a tertiary care center of Saudi Arabia. Am J Infect Control. 2005;33(3):144–50.PubMed
21.
22.
Luman ET, McCauley MM, Stokley S, Chu SY, Pickering LK. Timeliness of childhood immunizations. Pediatrics. 2002;110(5):935–9.PubMed
23.
Wu J, Li D, Zhou Y. Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series. Int J Infect Dis. 2016;51:62–5.PubMed
24.
25.
Wallace AS, Sobel H, Ryman TK, Mantaring JB, Silvestre M, Thorley M, et al. Timing of hepatitis B vaccination and impact of non-simultaneous vaccination with DTP vaccine following introduction of a hepatitis B birth dose in the Philippines. J Public Health Policy. 2012;33(3):368–81.PubMed
26.
• Whitford K, Liu B, Micallef J, Yin JK, Macartney K, Van Damme P, et al. Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bull World Health Organ. 2018;96(7):484–97 A systematic review and meta-analysis of the long-term impact of newborn vaccination on hepatitis B prevalence. This study also provides definitions for primary and secondary vaccine failure. PubMedPubMedCentral
27.
Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013;31(21):2506–16.PubMed
28.
Lai M-W, Lin T-Y, Tsao K-C, Huang C-G, Hsiao M-J, Liang K-H, et al. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology. 2012;143(2):400–7.PubMed
29.
Wu T-W, Lin HH, Wang L-Y. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(1):37–45.PubMed
30.
•• Tai C-S, Wu J-F, Chen H-L, Ni Y-H, Hsu H-Y, Chang M-H. The impact of hepatitis B vaccine failure on long-term natural course of chronic hepatitis B virus infection in hepatitis B e antigen-seropositive children. J Infect Dis. 2017;216(6):662–9 A large cohort study from Taiwan that reports long-term consequences of vaccine failure. PubMed
31.
Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–102.PubMed
32.
Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19(2):e18–25.PubMed
33.
Lin X, Guo Y, Zhou A, Zhang Y, Cao J, Yang M, et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis. Pediatr Infect Dis J. 2014;33(9):897–903.PubMed
34.
Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet. 1988;2(8620):1132–3.PubMed
35.
Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine. 2007;25(17):3482–4.PubMed
36.
André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87(3A):14S–20S.PubMed
37.
Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis. 2002;35(11):1368–75.PubMed
38.
de Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine. 1994;12(6):532–4.PubMed
39.
Alavian S-M, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine. 2010;28(22):3773–7.PubMed
40.
Jiang H-Y, Wang S-Y, Deng M, Li Y-C, Ling Z-X, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633–41.PubMed
41.
de Mattos AA, Gomes EB, Tovo CV, Alexandre COP, Remião JO d R. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol. 2004;41(3):180–4.PubMed
42.
Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902–8.PubMed
43.
Fan W, Chen X-F, Shen C, Guo Z-R, Dong C. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine. 2016;34(40):4835–41.PubMed
44.
Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine. 1994;12(9):771–2.PubMed
45.
Li Z-K, Nie J-J, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine. 2013;31(40):4355–61.PubMed
46.
Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39(4):978–88.PubMed
47.
Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179(2):489–92.PubMed
48.
Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307(24):1481–6.PubMed
49.
• Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed healthcare workers, but does not provide sterilizing immunity. Gastroenterology. 2013;145(5). Available from: https://​www.​ncbi.​nlm.​nih.​gov/​pmc/​articles/​PMC3884684/​.​ Describes how HBsAg vaccine protects against chronic infection but is not sterilizing, as evidenced by HBcore- and polymerase-specific CD8+ T cells in vaccinated personnel.):1026–34.PubMed
50.
Keating SM, Heitman JD, Wu S, Deng X, Stramer SL, Kuhns MC, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis. 2014;209(6):845–54.PubMed
51.
• O’Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, et al. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J Clin Virol. 2011;52(2):151–4 A case report of secondary vaccine failure in an immune competent adult resulting in the development of chronic hepatitis B. Escape mutants were not detected. PubMed
52.
Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351(27):2832–8.PubMed
53.
Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006;24(3):497–506.PubMed
54.
Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. Dig Dis Sci. 2012;57(1):215–20.PubMed
55.
Kim Y-C, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res. 2011;1(1):7–12.PubMedPubMedCentral
56.
Betancourt AA, Delgado CAG, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SRM, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11(5):394–401.PubMed
57.
Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci. 2007;32(4–5):278–90.PubMed
58.
Soares E, Jesus S, Borges O. Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming. Int J Pharm. 2018;535(1):261–71.PubMed
59.
Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299–304.PubMed
60.
Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000;31(1):230–4.PubMed
61.
Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis. C. Am J Gastroenterol. 2002;97(2):435–9.PubMed
62.
63.
Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.PubMed
64.
Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409.PubMedPubMedCentral
65.
Mahboubi A, Fazeli MR, Dinarvand R, Samadi N, Sharifzadeh M, Ilka H, et al. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice. Iran J Immunol. 2008;5(3):163–70.PubMed
66.
Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31(15):1999–2007.PubMedPubMedCentral
67.
Alavian S-M, Tabatabaei S-V. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther. 2010;32(1):1–10.PubMed
68.
•• A two-dose hepatitis B vaccine for adults (Heplisav-B). JAMA 2018;319(8):822–3. A review article describing a two-dose hepatitis B vaccine.
69.
Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. 2006;24(1):20–6.PubMed
70.
Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine. 2012;30(15):2556–63.PubMed
71.
Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5.PubMed
72.
• Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36(5):668–74 A large phase III randomized controlled trial comparing a novel two-dose hepatitis B vaccine against a second generation vaccine. PubMed
73.
•• Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455–8 The CDC recommendations regarding a two-dose hepatitis B vaccine. PubMedPubMedCentral
74.
Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in neonates. Pediatr Infect Dis J. 1997;16(6):587–92.PubMed
75.
Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in adults. Isr Med Assoc J. 2001;3(5):328–32.PubMed
76.
Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC, et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology. 2001;34(2):372–6.PubMed
77.
Krawczyk A, Ludwig C, Jochum C, Fiedler M, Heinemann FM, Shouval D, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014;32(39):5077–82.PubMed
78.
• Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018;22(1):151–8 A randomized controlled trial comparing immunogenicity in the third-generation vaccine against the second generation vaccine in dialysis patients. PubMed
79.
Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, et al. Sci-B-VacTM vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial. J Crohns Colitis. 2016;10(8):905–12.PubMedPubMedCentral
Metadata
Title
New Advances in Hepatitis B Vaccination for Adults
Authors
Qingyao Daniel Huang
Seng-Gee Lim
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0435-5

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?

Fatty Liver Disease (Z Younossi, Section Editor)

The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Fatty Liver Disease (Z Younossi, Section Editor)

The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality

Hepatitis B (J Lim, Section Editor)

Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice

Hepatitis B (J Lim, Section Editor)

Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits